Apogee Therapeutics announced positive Phase 2 data for APG777, an anti-IL-13 monoclonal antibody that significantly reduced symptoms of moderate-to-severe atopic dermatitis compared to placebo. The study met primary and secondary endpoints with a 71% reduction in disease severity at 16 weeks and superior skin clearance rates relative to competitors Dupixent and Ebglyss. APG777’s extended half-life may permit quarterly or biannual maintenance dosing, offering a potential advantage in convenience over existing therapies.